1. Volume 134, Issue 5, Pages 1352-1359 (May 2008)
Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study 
Marta Martín–Llahí, Marie–Noëlle Pépin, Mónica Guevara, Fernando Díaz, Aldo Torre, Alberto Monescillo, Germán Soriano, Carlos Terra, Emilio Fábrega, Vicente Arroyo, Juan Rodés, Pere Ginès 
Gastroenterology 
Volume 134, Issue 5, Pages (May 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1 Flow chart of patients included in the study.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
Inverse Kaplan–Meier curves estimating the cumulative incidence of improvement of renal function. The median time to improvement of renal function in patients treated with terlipressin and albumin was 11 days (95% CI: 6.1–15.9). Improvement of renal function was defined either as reduction in serum creatinine below 133 μmol/L at the end of treatment (complete response) or reduction in serum creatinine of greater than 50% of the pretreatment value but with an end-of-treatment value equal to or greater than 133 μmol/L (partial response).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

4. Figure 3
Probability of survival at 3 months of patients included in the study, classified according to improvement of renal function during randomized treatment (left graph) and base-line model for end-stage liver disease (MELD) score (right graph). MELD score could not be calculated in 2 patients.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions